Wound treatment is a major healthcare cost for all developed countries. In the UK for example, it is estimated that up to 4% of all health care costs are due to wounds . However, this represents only some 15-20% of the overall cost of wound treatment, where hospitalization and nurse time represent the remaining costs. The main driver for growth is the treatment of chronic and complex wounds in an aging population, complicated by the increase in diabetes and other metabolic disorders. Ideally, wounds at-risk of becoming chronic in high-risk patients should be treated from the outset with the most effective products (such as collagen based dressings), however, due to cost considerations, this is not the case. This was confirmed through extensive interactions with KOLs in the UK and France which also stated that wound care for chronic wounds is still an unsolved matter.
The direct and societal cost in the treatment of delayed and chronic wounds is a significant problem in all major developed countries. Efficiency in wound healing is now a critical element in the struggle to maintain service levels in face of an aging population with its increased level of complex illnesses such as diabetes and venous insufficiency both of which lead to chronic leg wounds and ulcers. At the same time the National Health Service budget assumption is for zero budget growth between 2015 and 2020 in real terms. The conflicting trends in the UK are typical of that of all EU countries. Clearly, costs must be reduced per patient in this scenario. In most socialized medicine countries, presently most pressure is applied to driving down consumable costs.
Wound healing products have remained largely unchanged for the last 20 years. Collagen products today have limited use as they are seen as expensive (up to 10 times as expensive as non-collagen products ). Supply and safety of mammalian derived materials have also limited the usage of such products. In this scenario, effective wound care products, such as collagen based dressings, but with a significantly lower cost, become an attractive solution.
The concept behind DermaRep – the only EggShell Membrane (ESM) based wound dressing - directly addresses the healthcare industry needs by providing a novel wound care product that it as effective as the existing collagen based dressings, but it is also:
- significantly lower in cost (at least 3 fold lower cost)
- much more easily scalable,
- significantly safer
The combination of product scalability, effectiveness and cost represent a breakthrough in the wound healing market. This will allow for the first time an advanced product to be become the standard of care, reducing both product cost and nursing time. With DermaRep, BIOVOTEC will, therefore, be in a privileged position to seize a major market opportunity within the healthcare sector.
